First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: Should we stop separating cisplatin-eligible and -ineligible patients?

Guru Sonpavde, Matthew D. Galsky, Nicholas J. Vogelzang

Research output: Contribution to journalLetterpeer-review

18 Scopus citations
Original languageEnglish
Pages (from-to)e441-e442
JournalJournal of Clinical Oncology
Volume28
Issue number25
DOIs
StatePublished - 1 Sep 2010

Cite this